FDA approves AbbVie combo hepatitis C treatment

Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.

The Food and Drug Administration approved the sale of a packaged treatment called Viekira (vee-KEE'-rah) Pak made by AbbVie Inc. of North Chicago, Illinois.

It includes a , which contains the ombitasvir, paritaprevir and ritonavir, along with a tablet of dasabuvir. All the ingredients are new except for ritonavir, which works to increase blood levels of paritaprevir.

It's among several new pill-only hepatitis C treatments that are big improvements over earlier treatments that are less effective, require injections and cause flu-like side effects.

About 3.2 million Americans are infected with hepatitis C, which generally doesn't cause noticeable symptoms until the liver is damaged.


Explore further

Bristol-Myers: FDA blocks hepatitis C drug for now

© 2014 The Associated Press. All rights reserved.

Citation: FDA approves AbbVie combo hepatitis C treatment (2014, December 19) retrieved 24 May 2019 from https://medicalxpress.com/news/2014-12-fda-abbvie-combo-hepatitis-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more